Marshall Wace, LLP Kodiak Sciences Inc. Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

A detailed history of Marshall Wace, LLP transactions in Kodiak Sciences Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 40,015 shares of KOD stock, worth $350,131. This represents 0.0% of its overall portfolio holdings.

Number of Shares

40,015

Previous 166,425 75.96%

Holding current value

$350,131

Previous $391,000 73.4%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$2.2 - $3.25 $278,102 - $410,832	-126,410 Reduced 75.96%	40,015 $104,000
Q2 2024 Aug 14, 2024	BUY	$2.29 - $4.48 $112,049 - $219,206	48,930 Added 41.64%	166,425 $391,000
Q1 2024 May 15, 2024	BUY	$3.01 - $7.45 $353,659 - $875,337	117,495 New	117,495 $618,000
Q2 2023 Aug 14, 2023	SELL	$4.3 - $9.48 $433,246 - $955,157	-100,755 Reduced 72.84%	37,565 $259,000
Q1 2023 May 15, 2023	BUY	$4.81 - $8.88 $665,319 - $1.23 Million	138,320 New	138,320 $857,000
Q3 2022 Nov 14, 2022	SELL	$7.57 - $12.5 $2.5 Million - $4.14 Million	-330,904 Reduced 61.08%	210,860 $1.63 Million
Q2 2022 Aug 15, 2022	SELL	$5.04 - $9.48 $603,655 - $1.14 Million	-119,773 Reduced 18.11%	541,764 $4.14 Million
Q1 2022 May 16, 2022	BUY	$7.09 - $89.45 $4.69 Million - $59.2 Million	661,537 New	661,537 $5.11 Million
Q4 2020 Feb 16, 2021	SELL	$60.78 - $154.03 $933,337 - $2.37 Million	-15,356 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$45.05 - $59.27 $691,787 - $910,150	15,356 New	15,356 $909,000
Q3 2019 Nov 14, 2019	SELL	$10.24 - $17.57 $1 Million - $1.72 Million	-97,764 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$6.2 - $12.0 $360,672 - $698,076	58,173 Added 146.93%	97,764 $1.14 Million
Q1 2019 May 14, 2019	BUY	$6.43 - $9.44 $254,570 - $373,739	39,591 New	39,591 $258,000

Others Institutions Holding KOD

# of Institutions

Shares Held

39M

Call Options Held

6.5K

Put Options Held

5.8K

View Full List

About Kodiak Sciences Inc.

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $455M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

More about KOD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Kodiak Sciences Inc. Transaction History